| Current Price | $46.19 | Mkt Cap | $7.2B |
|---|---|---|---|
| Open | $46.41 | P/E Ratio | 0.00 |
| Prev. Close | $46.81 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $45.50 - $47.14 | Volume | 1,760,898 |
| 52-Wk Range | $15.73 - $47.79 | Avg. Daily Vol. | 1,526,689 |
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
| Current Price | $46.19 | Mkt Cap | $7.2B |
|---|---|---|---|
| Open | $46.41 | P/E Ratio | 0.00 |
| Prev. Close | $46.81 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $45.50 - $47.14 | Volume | 1,760,898 |
| 52-Wk Range | $15.73 - $47.79 | Avg. Daily Vol. | 1,526,689 |
The best Bull and Bear pitches based on recency and number of recommendations.
Nuplazid is the first drug approved for the treatment of PD psychosis. This market represents a 2-3B peak in sales. If Pimavanserin successfully expands its label to Alzheimer psychosis, Alzheimer agitation, schizo IRAT, then you have a company with… More
This article does a good job of laying out the bear case: http://seekingalpha.com/article/4015176-acadias-nuplazid-blockbuster-drug-imaginedThe market may turn out to be smaller than expected, especially with the black box warning ("Side effects… More
Read the most recent pitches from players about ACAD.
Recs
jahnjf
(46.31)
Submitted: 4/30/2018 4:19:11 PM :
Start Price:
$15.84
NASDAQ:ACAD Score:
+173.86
Currently slightly overvalued but if willing to risk that it gets approval for treatment of dementia and Alzheimer's, it will be an outperformer.
Recs
MarkBiotech
(< 20)
Submitted: 4/5/2017 3:48:38 AM :
Start Price:
$29.43
NASDAQ:ACAD Score:
+27.17
Nuplazid is the first drug approved for the treatment of PD psychosis. This market represents a 2-3B peak in sales. If Pimavanserin successfully expands its label to Alzheimer psychosis, Alzheimer agitation, schizo IRAT, then you have a company with unlimited potential.
2nd half of 2016 sales on Nuplazid were encouraging and prompted more confidence in my long position in Acadia. Nuplazid consensus of 90m sales in 2017 seems very conservative. All said and done, Acadia seems to be on the right track to becoming a pharmaceutical powerhouse.
LT Closing limit PT- 100
Recs
constructive
(99.97)
Submitted: 3/3/2017 4:05:27 PM :
Start Price:
$4.83
NASDAQ:ACAD Score:
-741.12
This article does a good job of laying out the bear case: http://seekingalpha.com/article/4015176-acadias-nuplazid-blockbuster-drug-imagined
The market may turn out to be smaller than expected, especially with the black box warning ("Side effects include death"). Most of the market is covered by Medicare, and pricing could be under pressure. Cash burn is also very high.
Find the members with the highest scoring picks in ACAD.
jamrod02 (64.28) Score: +5,750.20
The Score Leader is the player with the highest score across all their picks in ACAD.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| jamrod02 | 64.28 | 12/20/2010 |
|
5Y | $0.77 | +5,899.48% | +149.28% | +5,750.20 | 0 Comment | |
| noobtery | < 20 | 10/28/2010 |
|
5Y | $0.83 | +5,465.06% | +161.40% | +5,303.66 | 0 Comment | |
| Hornet41 | 61.35 | 12/22/2010 |
|
5Y | $0.90 | +5,031.65% | +147.61% | +4,884.04 | 0 Comment | |
| Ruckwerts | 60.49 | 12/1/2011 |
|
3Y | $0.93 | +4,866.67% | +149.02% | +4,717.65 | 0 Comment | |
| dsherid2 | 59.41 | 11/30/2011 |
|
1Y | $1.03 | +4,384.90% | +150.08% | +4,234.82 | 0 Comment | |
| Smog79 | < 20 | 8/12/2010 |
|
3W | $1.04 | +4,341.35% | +186.07% | +4,155.28 | 0 Comment | |
| drmanand | 64.52 | 7/14/2010 |
|
1Y | $1.11 | +4,062.01% | +184.24% | +3,877.77 | 1 Comment | |
| smallandmidcap | 95.37 | 8/10/2010 |
|
5Y | $1.13 | +3,987.61% | +177.34% | +3,810.27 | 0 Comment | |
| dmkj50 | 41.15 | 10/27/2011 |
|
5Y | $1.17 | +3,847.53% | +142.87% | +3,704.66 | 0 Comment | |
| tappo3833 | 88.89 | 1/3/2011 |
|
1Y | $1.19 | +3,781.51% | +145.21% | +3,636.31 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
